Teva Pharmaceutical Industries - TEVA Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $10.88
Forecasted Upside: 5.07%
Number of Analysts: 9
Breakdown:
2 Sell Ratings
4 Hold Ratings
3 Buy Ratings
0 Strong Buy Ratings

^$10.35 As of 09/22/2023 01:00 AM ET

▲ +0.01 (0.10%)

1 month | 3 months | 12 months

Get New Teva Pharmaceutical Industries Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for TEVA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TEVA

^$10.88

▲ +5.07% Upside Potential

This price target is based on 9 analysts offering 12 month price targets for Teva Pharmaceutical Industries in the last 3 months. The average price target is $10.88, with a high forecast of $14.00 and a low forecast of $7.00. The average price target represents a 5.07% upside from the last price of $10.35.

Current Consensus is Hold

The current consensus among 9 contributing investment analysts is to hold stock in Teva Pharmaceutical Industries. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
3 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

3/31/2022

0 strong buy ratings
3 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

6/29/2022

0 strong buy ratings
3 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

9/27/2022

0 strong buy ratings
3 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

12/26/2022

0 strong buy ratings
3 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

3/26/2023

0 strong buy ratings
3 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

6/24/2023

0 strong buy ratings
3 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

8/23/2023

0 strong buy ratings
3 buy ratings
4 hold ratings
2 sell ratings

Ratings as of

9/22/2023

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
9/20/2023	UBS Group	Boost Target	Neutral ➝ Neutral	$8.00 ➝ $11.00	Low
9/8/2023	Bank of America	Boost Target	Buy ➝ Buy	$12.00 ➝ $13.00	Low
7/6/2023	UBS Group	Upgrade	Sell ➝ Neutral	$7.00 ➝ $8.00	Low
5/25/2023	Morgan Stanley	Initiated Coverage	Equal Weight	$10.00	Low
5/18/2023	Evercore ISI	Upgrade	In-Line ➝ Outperform		Low
2/9/2023	Barclays	Boost Target	Overweight	$13.00 ➝ $14.00	Low
1/19/2023	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$10.00 ➝ $12.00	Low
11/23/2022	Piper Sandler	Lower Target	Underweight	$8.00 ➝ $7.00	Low
11/14/2022	JPMorgan Chase & Co.	Downgrade	Neutral ➝ Underweight	$11.00 ➝ $10.00	Low
11/7/2022	BMO Capital Markets	Lower Target	Market Perform	$11.00 ➝ $10.00	Low
11/4/2022	UBS Group	Downgrade	Neutral ➝ Sell		Low
10/21/2022	Jefferies Financial Group	Reiterated Rating	Buy	$10.00	Low
8/5/2022	Bank of America	Upgrade	Neutral ➝ Buy	$10.00 ➝ $13.00	Low
8/2/2022	The Goldman Sachs Group	Boost Target	Neutral	$9.00 ➝ $10.00	Low
6/13/2022	UBS Group	Initiated Coverage	Neutral	$10.00	Low
5/17/2022	Bank of America	Upgrade	Underperform ➝ Neutral	$9.00	N/A
5/4/2022	Piper Sandler	Downgrade	Neutral ➝ Underweight	$11.00 ➝ $7.00	Low
4/5/2022	Barclays	Upgrade	Equal Weight ➝ Overweight	$11.00 ➝ $13.00	N/A
3/25/2022	Sanford C. Bernstein	Upgrade	Market Perform ➝ Outperform	$11.00	Medium
2/18/2022	Barclays	Lower Target	Equal Weight	$13.00 ➝ $11.00	Medium
1/27/2022	Argus	Downgrade	Buy ➝ Hold		Medium
10/28/2021	Raymond James	Downgrade	Outperform ➝ Market Perform		High
7/29/2021	Raymond James	Lower Target	Outperform	$15.00 ➝ $14.00	Medium
7/29/2021	Wells Fargo & Company	Lower Target	Equal Weight	$12.00 ➝ $11.00	Medium
5/10/2021	UBS Group	Reiterated Rating	Buy ➝ Neutral	$15.00 ➝ $11.00	N/A
5/4/2021	UBS Group	Downgrade	Buy ➝ Neutral	$15.00 ➝ $11.00	High
3/14/2021	JPMorgan Chase & Co.	Reiterated Rating	Hold	$10.00	Medium
12/28/2020	Raymond James	Reiterated Rating	Buy		N/A
11/24/2020	Oppenheimer	Initiated Coverage	Market Perform		Low
11/6/2020	BMO Capital Markets	Lower Target	Market Perform	$13.00 ➝ $11.00	High
10/23/2020	Raymond James	Reiterated Rating	Buy		Low
10/13/2020	Argus	Lower Target	Average ➝ Buy	$14.00 ➝ $11.00	Low
9/14/2020	Raymond James	Reiterated Rating	Buy		Low
8/26/2020	Bank of America	Reiterated Rating	Sell	$8.00	Low
8/6/2020	SVB Leerink	Boost Target	Market Perform	$13.00 ➝ $14.00	Medium
8/6/2020	Barclays	Upgrade	Underweight ➝ Equal Weight	$10.00 ➝ $13.00	Medium
7/27/2020	The Goldman Sachs Group	Initiated Coverage	Neutral	$12.00	Low
6/1/2020	SunTrust Banks	Upgrade	Hold ➝ Buy	$11.00 ➝ $16.00	High
5/11/2020	UBS Group	Boost Target	Buy	$12.00 ➝ $15.00	Medium
5/8/2020	Cantor Fitzgerald	Reiterated Rating	Neutral		Low
5/8/2020	SVB Leerink	Boost Target	Market Perform	$11.00 ➝ $12.00	Low
5/8/2020	Bank of America	Reiterated Rating	Underperform	$7.00 ➝ $8.00	Low
4/24/2020	Citigroup	Initiated Coverage	Neutral		Low
4/17/2020	Barclays	Reiterated Rating	Sell	$9.00	Low
4/15/2020	Piper Sandler	Lower Target	Neutral	$10.00 ➝ $8.00	Low
4/6/2020	UBS Group	Upgrade	Neutral ➝ Buy	$14.00 ➝ $12.00	High
4/2/2020	Morgan Stanley	Lower Target	Underweight	$13.00 ➝ $8.00	Medium
3/23/2020	Bank of America	Lower Target	Underperform	$11.00 ➝ $7.00	Low
3/5/2020	Wells Fargo & Company	Boost Target	Equal Weight	$10.00 ➝ $12.00	Low
2/24/2020	Edward Jones	Downgrade	Hold ➝ Sell		High
2/18/2020	Argus	Boost Target	Buy	$10.00 ➝ $15.00	Low
2/17/2020	UBS Group	Boost Target	Neutral	$8.00 ➝ $14.00	Medium
2/14/2020	Morgan Stanley	Boost Target	Underweight	$8.00 ➝ $13.00	High
2/13/2020	Bank of America	Boost Target	Underperform	$8.00 ➝ $11.00	High
2/13/2020	SunTrust Banks	Boost Target	Hold	$9.00 ➝ $13.00	Medium
2/13/2020	Oppenheimer	Boost Target	Outperform	$12.00 ➝ $16.00	High
2/12/2020	Cantor Fitzgerald	Boost Target	In-Line ➝ Neutral	$9.00 ➝ $15.00	Low
2/12/2020	Cfra	Boost Target	Hold	$11.00 ➝ $13.00	Low
1/22/2020	Wells Fargo & Company	Boost Target	Equal Weight	$8.00 ➝ $10.00	Medium
1/3/2020	Bank of America	Upgrade	Underperform ➝ Buy		High
11/12/2019	JPMorgan Chase & Co.	Upgrade	Underweight ➝ Neutral	$8.00	Medium
10/16/2019	Gabelli	Upgrade	Hold ➝ Buy		High
9/30/2019	Wells Fargo & Company	Lower Target	Market Perform	$17.00 ➝ $8.00	Low
9/12/2019	Guggenheim	Initiated Coverage	Neutral		Low
9/6/2019	JPMorgan Chase & Co.	Lower Target	Underweight	$9.00 ➝ $7.00	Low
8/16/2019	UBS Group	Set Target	Hold	$8.00	High
8/9/2019	BMO Capital Markets	Lower Target	Market Perform	$11.00 ➝ $9.00	N/A
8/8/2019	Royal Bank of Canada	Reiterated Rating	Hold	$10.00	High
8/8/2019	SunTrust Banks	Lower Target	Hold	$7.00	Medium
8/8/2019	Raymond James	Lower Target	Outperform	$22.00 ➝ $15.00	Medium
8/7/2019	Cowen	Set Target	Hold	$9.00	Low
7/19/2019	Wolfe Research	Initiated Coverage	Peer Perform ➝ Peer Perform	$9.00	Low
7/15/2019	Morgan Stanley	Downgrade	Equal Weight ➝ Underweight	$16.00 ➝ $6.00	High
7/10/2019	Credit Suisse Group	Reiterated Rating	Neutral		Low
7/5/2019	Argus	Upgrade	Hold ➝ Buy	$12.00	High
6/18/2019	Sanford C. Bernstein	Lower Target	Market Perform	$17.00 ➝ $11.00	Medium
6/17/2019	Mizuho	Set Target	Hold	$11.00	Medium
6/17/2019	Citigroup	Set Target	Buy	$23.00 ➝ $13.00	Low
6/12/2019	Oppenheimer	Set Target	Buy	$12.00	High
6/12/2019	Cantor Fitzgerald	Lower Target	Neutral	$16.00 ➝ $9.00	Low
6/11/2019	Barclays	Initiated Coverage	Underweight ➝ Underweight	$8.00	Medium
6/3/2019	CIBC	Upgrade	Market Perform ➝ Outperform	$12.00	Medium
6/3/2019	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$12.00	Low
5/30/2019	Bank of America	Downgrade	Buy ➝ Underperform	$19.00 ➝ $9.00	High
5/28/2019	Wells Fargo & Company	Set Target	Hold	$17.00	Medium
5/28/2019	UBS Group	Downgrade	Buy ➝ Neutral	$22.00 ➝ $12.00	High
5/10/2019	Wells Fargo & Company	Reiterated Rating	Hold		High
5/9/2019	Wells Fargo & Company	Lower Target	Market Perform	$18.00 ➝ $17.00	Low
5/3/2019	Royal Bank of Canada	Set Target	Hold	$19.00	Low
5/3/2019	BMO Capital Markets	Set Target	Hold	$17.00	Low
5/3/2019	Morgan Stanley	Set Target	Hold	$16.00	Low
5/3/2019	Cantor Fitzgerald	Boost Target	Positive ➝ Neutral	$16.00 ➝ $25.00	Medium
5/2/2019	Maxim Group	Reiterated Rating	Hold		Low
4/11/2019	Citigroup	Lower Target	Buy	$27.00 ➝ $23.00	Low
4/3/2019	Wells Fargo & Company	Lower Target	Market Perform ➝ Market Perform	$20.00 ➝ $18.00	Low
3/28/2019	BMO Capital Markets	Initiated Coverage	Market Perform	$18.00	Medium
3/19/2019	SunTrust Banks	Initiated Coverage	Hold ➝ Hold	$17.00	Low
3/7/2019	UBS Group	Initiated Coverage	Buy	$22.00	Medium
3/6/2019	Morgan Stanley	Downgrade	Overweight ➝ Equal Weight	$17.00	High
2/20/2019	Mizuho	Downgrade	Buy ➝ Neutral	$25.00 ➝ $18.00	Medium
2/14/2019	Credit Suisse Group	Lower Target	Neutral ➝ Neutral	$26.00 ➝ $20.00	Medium
2/14/2019	Raymond James	Upgrade	Market Perform ➝ Outperform	$22.00	Medium
2/14/2019	Maxim Group	Reiterated Rating	Hold		Medium
2/14/2019	Wells Fargo & Company	Reiterated Rating	Hold	$24.00 ➝ $20.00	Medium
2/11/2019	Oppenheimer	Reiterated Rating	Hold		Medium
2/5/2019	Credit Suisse Group	Reiterated Rating	Hold	$26.00	High
2/5/2019	HSBC	Set Target	Sell	$12.00	High
2/5/2019	Bank of America	Reiterated Rating	Buy	$24.00	Low
1/23/2019	Piper Jaffray Companies	Upgrade	Underweight ➝ Neutral	$15.00 ➝ $16.00	Low
1/23/2019	UBS Group	Upgrade	Neutral ➝ Buy		Low
1/3/2019	Bank of America	Upgrade	Underperform ➝ Buy	$16.12	High
12/13/2018	Credit Suisse Group	Set Target	Hold	$26.00	Medium
11/7/2018	Oppenheimer	Reiterated Rating	Hold		Medium
11/5/2018	Morgan Stanley	Upgrade	Equal Weight ➝ Overweight	$20.00 ➝ $27.00	Low
11/2/2018	Bank of America	Boost Target	Underperform ➝ Underperform	$19.00 ➝ $20.00	Low
11/2/2018	Royal Bank of Canada	Set Target	Hold	$22.00	Low
11/2/2018	Wells Fargo & Company	Reiterated Rating	Hold		Low
11/1/2018	Maxim Group	Reiterated Rating	Hold		High
11/1/2018	Oppenheimer	Reiterated Rating	Hold		High
10/17/2018	Wells Fargo & Company	Set Target	Hold	$23.00	Low
10/17/2018	Oppenheimer	Reiterated Rating	Hold		Medium
10/14/2018	Credit Suisse Group	Set Target	Hold	$26.00	Medium
10/1/2018	The Goldman Sachs Group	Upgrade	Buy ➝ Conviction-Buy	$30.00	High
10/1/2018	SVB Leerink	Upgrade	Underperform ➝ Market Perform	$16.00 ➝ $24.00	High
9/27/2018	Wells Fargo & Company	Set Target	Hold	$23.00	Low
9/27/2018	Cantor Fitzgerald	Reiterated Rating	Hold	$25.00	High

(Data available from 9/23/2018 forward)

News Sentiment Rating

0.95 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

19 very positive mentions
16 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

2/25/2023

10 very positive mentions
19 positive mentions
4 negative mentions
0 very negative mentions

Mentions as of

3/27/2023

5 very positive mentions
16 positive mentions
5 negative mentions
1 very negative mentions

Mentions as of

4/26/2023

7 very positive mentions
24 positive mentions
6 negative mentions
2 very negative mentions

Mentions as of

5/26/2023

8 very positive mentions
16 positive mentions
4 negative mentions
0 very negative mentions

Mentions as of

6/25/2023

6 very positive mentions
6 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

7/25/2023

12 very positive mentions
16 positive mentions
3 negative mentions
0 very negative mentions

Mentions as of

8/24/2023

11 very positive mentions
7 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

9/23/2023

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also manufactures and sells active pharmaceutical ingredients, as well as provides contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. In addition, it focuses on the central nervous system (CNS), pain, respiratory, and oncology areas. The company's products portfolio in the CNS field comprises Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; and AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; respiratory therapeutic area includes ProAir RespiClick, QVAR, ProAir Digihaler, AirDuo Digihaler, ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease; and oncology therapeutic field consists of Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Today's Range

Now: $10.35

$10.32

$10.54

50 Day Range

MA: $9.49

$8.03

$10.70

52 Week Range

Now: $10.35

$7.09

$11.44

Volume

7,139,257 shs

Average Volume

7,759,255 shs

Market Capitalization

$11.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Teva Pharmaceutical Industries?: The following sell-side analysts have issued research reports on Teva Pharmaceutical Industries in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Evercore ISI, Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, StockNews.com, and UBS Group AG.
View the latest analyst ratings for TEVA.
What is the current price target for Teva Pharmaceutical Industries?: 8 Wall Street analysts have set twelve-month price targets for Teva Pharmaceutical Industries in the last year. Their average twelve-month price target is $10.88, suggesting a possible upside of 5.1%. Barclays PLC has the highest price target set, predicting TEVA will reach $14.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $7.00 for Teva Pharmaceutical Industries in the next year.
View the latest price targets for TEVA.
What is the current consensus analyst rating for Teva Pharmaceutical Industries?: Teva Pharmaceutical Industries currently has 2 sell ratings, 4 hold ratings and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in TEVA, but not buy more shares or sell existing shares.
View the latest ratings for TEVA.
What other companies compete with Teva Pharmaceutical Industries?: Other companies that are similar to Teva Pharmaceutical Industries include Dr. Reddy's Laboratories, Viatris, Verona Pharma, Legend Biotech and Sarepta Therapeutics. Learn More about companies similar to Teva Pharmaceutical Industries.
How do I contact Teva Pharmaceutical Industries' investor relations team?: Teva Pharmaceutical Industries' physical mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company's listed phone number is (723) 914-8213 and its investor relations email address is [email protected]. The official website for Teva Pharmaceutical Industries is www.tevapharm.com. Learn More about contacing Teva Pharmaceutical Industries investor relations.

Teva Pharmaceutical Industries - TEVA Stock Price Target and Predictions

Analyst Price Target for TEVA

Current Consensus is Hold

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.95 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Teva Pharmaceutical Industries?

What is the current price target for Teva Pharmaceutical Industries?

What is the current consensus analyst rating for Teva Pharmaceutical Industries?

What other companies compete with Teva Pharmaceutical Industries?

How do I contact Teva Pharmaceutical Industries' investor relations team?